Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MDMA: on the translation from rodent to human dosing.

× No keyword cloud information.

29 in total

1. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose.

Authors: B Esteban; E O'Shea; J Camarero; V Sanchez; A R Green; M I Colado
Journal: Psychopharmacology (Berl) Date: 2001-03 Impact factor: 4.530

2. MDMA, politics and medical research: have we thrown the baby out with the bathwater?

Authors: Ben Sessa; David J Nutt
Journal: J Psychopharmacol Date: 2007-11 Impact factor: 4.153

3. Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with the bath water) in the November 2007 journal.

Authors: B Sessa; D Nutt
Journal: J Psychopharmacol Date: 2008-06 Impact factor: 4.153

4. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

Authors: Cándido Hernández-López; Magí Farré; Pere N Roset; Esther Menoyo; Nieves Pizarro; Jordi Ortuño; Marta Torrens; Jordi Camí; Rafael de La Torre
Journal: J Pharmacol Exp Ther Date: 2002-01 Impact factor: 4.030

5. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors: M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal: J Pharmacol Exp Ther Date: 1999-07 Impact factor: 4.030

6. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors: R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal: Br J Clin Pharmacol Date: 2000-02 Impact factor: 4.335

7. High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding.

Authors: E R Garrett; K Seyda; P Marroum
Journal: Acta Pharm Nord Date: 1991

8. Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA.

Authors: A Richard Green; Veronica Sanchez; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal: Psychopharmacology (Berl) Date: 2004-01-15 Impact factor: 4.530

9. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat.

Authors: Vijay V Upreti; Natalie D Eddington
Journal: J Pharm Sci Date: 2008-04 Impact factor: 3.534

10. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors: Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal: Ther Drug Monit Date: 2008-06 Impact factor: 3.681

21 in total

1. Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors: Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal: Psychopharmacology (Berl) Date: 2010-07-20 Impact factor: 4.530

2. Comment on the letter by Green, Gabrielsson, Marsden, and Fone, MDMA: on the translation from rodent to human dosing.

Authors: Rafael de la Torre; Elena Puerta; Norberto Aguirre
Journal: Psychopharmacology (Berl) Date: 2009-01-16 Impact factor: 4.530

3. MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate.

Authors: Courtney L Huff; Rachel L Morano; James P Herman; Bryan K Yamamoto; Gary A Gudelsky
Journal: Neurotoxicology Date: 2016-10-20 Impact factor: 4.294

Review 4. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors: J R Docherty; A R Green
Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739

5. Sensitization to the motor stimulant effects of 3,4-methylenedioxypyrovalerone (MDPV) and cross-sensitization to methamphetamine in rats.

Authors: Lucas R Watterson; Peter R Kufahl; Sara B Taylor; Natali E Nemirovsky; M Foster Olive
Journal: J Drug Alcohol Res Date: 2016-05

6. The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI).

Authors: Shahaf Edut; Vardit Rubovitch; Shaul Schreiber; Chaim G Pick
Journal: Psychopharmacology (Berl) Date: 2010-12-01 Impact factor: 4.530

Review 7. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors: A R Green; M V King; S E Shortall; K C F Fone
Journal: Br J Pharmacol Date: 2012-07 Impact factor: 8.739

8. 3,4-Methylenedioxymethamphetamine (MDMA) alters acute gammaherpesvirus burden and limits interleukin 27 responses in a mouse model of viral infection.

Authors: Daniel A Nelson; Sam J Singh; Amy B Young; Melanie D Tolbert; Kenneth L Bost
Journal: Drug Alcohol Depend Date: 2011-01-26 Impact factor: 4.492

9. Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.

Authors: Marta Rodríguez-Arias; Concepción Maldonado; Antonio Vidal-Infer; Consuelo Guerri; María A Aguilar; José Miñarro
Journal: Psychopharmacology (Berl) Date: 2011-05-10 Impact factor: 4.530

10. Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.

Authors: Michael H Baumann; Dorota Zolkowska; Insook Kim; Karl B Scheidweiler; Richard B Rothman; Marilyn A Huestis
Journal: Drug Metab Dispos Date: 2009-08-13 Impact factor: 3.922